S969
Clinical - Oligometastatic cancer
ESTRO 2026
Poster Discussion 1913 START-MET: A phase III randomized trial of SBRT plus standard of care in oligometastatic hormonecastration-sensitive oligometastatic prostate cancer Antonio J. Conde-Moreno 1 , Fernando López-Campos 2 , Alfonso Gómez-Iturriaga 3 , Patricia Willisch Santamaría 4 , Antonio Lazo Prados 5 , Sandra Fernández Alonso 6 , Yesika Ríos 7 , Gemma Sancho Pardo 8 , María A. Gómez-Aparicio 9 , Joel Masés 10 , Ignacio Visus 11 , Almudena Zapatero 12 , Sonia García Cabezas 13 , Pilar Samper 14 , Àlvar Roselló 15 , Marta López Valcarcel 16 , Ana M. Carballo Castro 17 , Beatriz Ruíz Herrero 18 , Noelia Sanmamed 19 , Rubén D. Ramírez Vargas 20 , Carmen Velilla 21 , Marta Bonet 22 , Jonathan Saavedra 23 , Berta Sanvictor 24 , Agustina Méndez Villamón 25 1 Radiation Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain. 2 Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain. 3 Radiation Oncology, Hospital Universitario de Cruces, Barakaldo, Spain. 4 Radiation Oncology, Hospital do Meixoeiro, Vigo, Spain. 5 Radiation Oncology, Hospital Clínico Virgen de la Victoria, Málaga, Spain. 6 Radiation Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain. 7 Radiation Oncology, Complejo Hospitalario de Badajoz, Badajoz, Spain. 8 Radiation Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 9 Radiation Oncology, Hospital Virgen de la Salud, Toledo, Spain. 10 Radiation Oncology, Hospital Clínic de Barcelona, Barcelona, Spain. 11 Radiation Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain. 12 Radiation Oncology, Hospital Universitario La Princesa, Madrid, Spain. 13 Radiation Oncology, Hospital Universitario Reina Sofía, Córdoba, Spain. 14 Radiation Oncology, Hospital Universitario Rey Juan Carlos, Móstoles, Spain. 15 Radiation Oncology, Institut Català d’Oncologia, Girona, Spain. 16 Radiation Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. 17 Radiation Oncology, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain. 18 Radiation Oncology, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain. 19 Radiation Oncology, Hospital Clínico San Carlos, Madrid, Spain. 20 Radiation Oncology, CHU de Ourense, Ourense, Spain. 21 Radiation Oncology, Hospital Universitario Lozano Blesa, Zaragoza, Spain. 22 Radiation Oncology, Hospital Universitario Arnau de Vilanova, Lleida, Spain. 23 Radiation Oncology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain. 24 Radiation Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain. 25 Radiation Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain
Conclusion: In this large, real-world multicentre cohort, SBRT demonstrated favourable survival and local control outcomes, comparable to clinical trials, with very low toxicity. These findings also highlight the potential prognostic relevance of oligometastatic disease subtypes in patient outcomes. References: Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open- label trial. Lancet. 2019;393(10185):2051-2058. doi:10.1016/S0140-6736(18)32487-5Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer
consensus recommendation. Lancet Oncol. 2020;21(1):e18-e28. doi:10.1016/S1470- 2045(19)30718-1 Keywords: Stereotactic body radiotherapy, Multicentre
Made with FlippingBook - Share PDF online